Pentoxifylline modulates the AKT/mTOR/AMPK pathway: potential role as an adjunct in cancer chemotherapy

Abstract

Targeting specific pathways involved in the growth and death of cells, such as AKT (signal transduction pathway promoting growth), mTOR (intracellular signaling pathway regulating cell cycle), and AMPK (coordination of growth, autophagy, and metabolism), is an established, effective strategy to inhibit cancer cell growth. Previously, we have shown that pentoxifylline (PTX), a clinically‐utilized non‐specific phosphodiesterase inhibitor, can inhibit growth and induce G1 arrest in prostate cancer cells. In the present studies, we examined the mechanism of PTX induced growth inhibition via modulation of growth/metabolic pathways, and the potential use of PTX as an adjunct in cancer chemotherapy. In prostate adenocarcinoma cells (LNCaP), we show PTX modulates the AKT pathway, as evidenced by the decreased phosphorylation of AKT. Downstream modulation of the mTOR pathway is indicated by decreased phosphorylation of mTOR, ribosomal S6K, and 4EBP1, and total cyclin D1. P‐mTOR levels return to baseline by 24h, while p‐S6K, p‐4EBP1, and cyclin D1 levels are suppressed for at least 48h, indicating a sustained decrease in the activity of cell growth pathway proteins. PTX also modulates the AMPK pathway, as revealed by modulation of downstream p‐RAPTOR, p‐ACC and p‐ULK. Both the AKT and AMPK pathways regulate the activation of cellular autophagy, an intracellular degradation system and determinant of cell survival. Treatment of LNCaP cells with PTX alone, and in combination with bafilomycin, a lysosomal degradation inhibitor, increased LC3‐II expression, indicating an induction of autophagic flux. Overall, PTX modulates both AKT and AMPK pathways, decreasing cell growth and increasing autophagy. Moreover, LNCaP cells treated with PTX were more susceptible to docetaxel (DOC; first‐line chemotherapy) induced cytotoxicity than DOC alone. Interestingly, the PTX/DOC combination decreased the expression of LC3 relative to PTX alone, suggesting activation of an alternate cell death pathway. Indeed, assessment of caspase cleavage, pBcl‐2, and annexin staining revealed a synergistic effect of PTX/DOC treatment on the induction of apoptosis. In summary, the findings provide a mechanistic basis for the potential use of PTX as an adjunct in the chemotherapy of prostate cancer. The ability of PTX to potentiate the effects of DOC on tumor growth inhibition in a mouse xenograft model is currently being assessed.Support or Funding InformationASPET SURF, P30ES006694, T32ES006694